CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Seattle Genetics, Inc. - SGEN CFD

    218.89
    0.34%
    0.20
    Low: 218.1
    High: 219.57
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.20
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Seagen Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 218.15
    Open* 218.23
    1-Year Change* 83.17%
    Day's Range* 218.1 - 219.57
    52 wk Range 116.08-217.51
    Average Volume (10 days) 1.12M
    Average Volume (3 months) 31.81M
    Market Cap 40.20B
    P/E Ratio -100.00K
    Shares Outstanding 188.63M
    Revenue 2.30B
    EPS -4.01
    Dividend (Yield %) N/A
    Beta 0.33
    Next Earnings Date Feb 13, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 218.89 0.84 0.39% 218.05 219.62 217.83
    Dec 7, 2023 218.15 2.30 1.07% 215.85 219.40 215.44
    Dec 6, 2023 215.62 0.52 0.24% 215.10 216.06 214.73
    Dec 5, 2023 215.18 2.59 1.22% 212.59 215.83 211.95
    Dec 4, 2023 213.03 0.48 0.23% 212.55 213.11 211.95
    Dec 1, 2023 212.02 -0.10 -0.05% 212.12 213.61 211.70
    Nov 30, 2023 212.49 -1.17 -0.55% 213.66 213.76 212.42
    Nov 29, 2023 213.48 -0.30 -0.14% 213.78 214.45 213.35
    Nov 28, 2023 214.07 0.06 0.03% 214.01 214.62 213.64
    Nov 27, 2023 213.82 1.61 0.76% 212.21 214.86 212.21
    Nov 24, 2023 214.32 1.61 0.76% 212.71 214.93 212.19
    Nov 22, 2023 212.47 -1.08 -0.51% 213.55 214.14 212.39
    Nov 21, 2023 213.62 0.17 0.08% 213.45 214.87 212.61
    Nov 20, 2023 211.73 -0.17 -0.08% 211.90 212.25 210.77
    Nov 17, 2023 211.91 -0.26 -0.12% 212.17 212.91 211.39
    Nov 16, 2023 212.78 0.44 0.21% 212.34 213.31 211.42
    Nov 15, 2023 211.95 -1.05 -0.49% 213.00 213.82 211.55
    Nov 14, 2023 213.63 0.14 0.07% 213.49 214.38 212.26
    Nov 13, 2023 213.16 0.67 0.32% 212.49 213.56 212.32
    Nov 10, 2023 213.00 0.04 0.02% 212.96 214.24 211.96

    Seattle Genetics, Inc. Events

    Time (UTC) Country Event
    Tuesday, February 13, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Seagen Inc Earnings Release
    Q4 2023 Seagen Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, April 25, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q1 2024 Seagen Inc Earnings Release
    Q1 2024 Seagen Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1962.41 1574.37 2175.54 916.713 654.7
    Revenue 1962.41 1574.37 2175.54 916.713 654.7
    Cost of Revenue, Total 410.058 311.565 217.72 43.952 88.293
    Gross Profit 1552.35 1262.81 1957.82 872.761 566.407
    Total Operating Expense 2575.38 2256.43 1578.68 1137.26 914.698
    Selling/General/Admin. Expenses, Total 820.963 716.19 533.835 373.932 252.596
    Research & Development 1344.36 1228.67 827.129 719.374 565.309
    Operating Income -612.97 -682.056 596.852 -220.545 -259.998
    Interest Income (Expense), Net Non-Operating 10.655 6.351 18.849 61.895 13.652
    Net Income Before Taxes -602.315 -675.705 615.701 -158.65 -246.346
    Net Income After Taxes -610.308 -674.471 613.67 -158.65 -222.693
    Net Income Before Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
    Net Income -610.308 -674.471 613.67 -158.65 -222.693
    Income Available to Common Excl. Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
    Income Available to Common Incl. Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
    Diluted Net Income -610.308 -674.471 613.67 -158.65 -222.693
    Diluted Weighted Average Shares 184.676 182.048 182.287 165.498 157.655
    Diluted EPS Excluding Extraordinary Items -3.30475 -3.70491 3.3665 -0.95862 -1.41253
    Diluted Normalized EPS -3.30475 -3.70491 3.3665 -0.95862 -1.37749
    Total Extraordinary Items 0
    Unusual Expense (Income) 8.5
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 603.832 519.719 528.15 510.3 497.502
    Revenue 603.832 519.719 528.15 510.3 497.502
    Cost of Revenue, Total 180.753 111.776 108.21 108.122 106.1
    Gross Profit 423.079 407.943 419.94 402.178 391.402
    Total Operating Expense 824.553 704.232 682.154 703.105 630.613
    Selling/General/Admin. Expenses, Total 236.932 206.441 216.101 210.378 220.259
    Research & Development 399.868 356.015 357.843 384.605 304.254
    Operating Income -220.721 -184.513 -154.004 -192.805 -133.111
    Interest Income (Expense), Net Non-Operating 12.084 14.4 10.176 4.278 -1.609
    Net Income Before Taxes -208.637 -170.113 -143.828 -188.527 -134.72
    Net Income After Taxes -211.528 -174.737 -148.171 -190.816 -134.827
    Net Income Before Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
    Net Income -211.528 -174.737 -148.171 -190.816 -134.827
    Income Available to Common Excl. Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
    Income Available to Common Incl. Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
    Diluted Net Income -211.528 -174.737 -148.171 -190.816 -134.827
    Diluted Weighted Average Shares 187.559 186.889 186.107 184.792 184.145
    Diluted EPS Excluding Extraordinary Items -1.12779 -0.93498 -0.79616 -1.0326 -0.73218
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.10354 -0.83064 -0.79616 -1.0326 -0.73218
    Unusual Expense (Income) 7 30
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 2802.53 2869.19 3062.38 1176.64 653.595
    Cash and Short Term Investments 1735.07 2160.04 2559.42 811.055 410.672
    Cash & Equivalents 319.94 424.834 558.424 274.562 78.186
    Short Term Investments 1415.13 1735.2 2001 536.493 332.486
    Total Receivables, Net 501.912 389.256 324.988 236.001 146.281
    Accounts Receivable - Trade, Net 501.912 389.256 324.988 236.001 146.281
    Total Inventory 427.211 200.663 116.136 85.932 53.239
    Prepaid Expenses 134.794 119.239 61.84 43.653 43.403
    Total Assets 3674.53 3719.6 4000.91 2205.87 1503.33
    Property/Plant/Equipment, Total - Net 294.917 267.962 258.18 220.721 103.82
    Property/Plant/Equipment, Total - Gross 551.67 480.444 434.2 365.086 225.004
    Accumulated Depreciation, Total -256.753 -212.482 -176.02 -144.365 -121.184
    Intangibles, Net 237.516 260.593 283.68 300 300.04
    Long Term Investments 0 100.83 57.283 49.194
    Other Long Term Assets, Total 64.895 47.184 21.161 176.55 122.009
    Total Current Liabilities 818.404 568.854 388.138 259.357 225.072
    Accounts Payable 207.851 114.824 78.067 52.292 44.179
    Accrued Expenses 610.553 454.03 279.941 207.065 147.293
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 30.13 0 33.6
    Total Liabilities 870.713 654.465 512.806 329.579 229.386
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 52.309 85.611 124.668 70.222 4.314
    Total Equity 2803.82 3065.14 3488.1 1876.29 1273.94
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.187 0.183 0.181 0.172 0.16
    Additional Paid-In Capital 4954.47 4607.82 4356.92 3359.12 2598.41
    Retained Earnings (Accumulated Deficit) -2154.35 -1544.04 -869.568 -1483.24 -1324.59
    Other Equity, Total 3.51 1.179 0.565 0.229 -0.04
    Total Liabilities & Shareholders’ Equity 3674.53 3719.6 4000.91 2205.87 1503.33
    Total Common Shares Outstanding 186.559 183.381 180.902 171.994 160.262
    Goodwill, Net 274.671 274.671 274.671 274.671 274.671
    Other Current Assets, Total 3.546
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 2551.59 2515.7 2601.91 2802.53 2759.62
    Cash and Short Term Investments 1236.99 1292.12 1490.27 1735.07 1763.7
    Cash & Equivalents 428.568 308.441 335.847 319.94 362.601
    Short Term Investments 808.418 983.678 1154.43 1415.13 1401.1
    Total Receivables, Net 631.555 586.048 495.777 501.912 486.755
    Accounts Receivable - Trade, Net 631.555 586.048 495.777 501.912 486.755
    Total Inventory 531.188 486.854 477.694 427.211 364.97
    Prepaid Expenses 151.272 149.856 136.979 134.794 138.423
    Total Assets 3634.26 3495.38 3543.3 3674.53 3619.08
    Property/Plant/Equipment, Total - Net 487.662 428.146 378.957 294.917 279.61
    Goodwill, Net 274.671 274.671 274.671 274.671 274.671
    Intangibles, Net 220.255 226.072 231.826 237.516 243.332
    Long Term Investments
    Other Long Term Assets, Total 100.08 50.797 55.931 64.895 61.846
    Total Current Liabilities 954.716 762.898 713.228 818.404 725.998
    Accounts Payable 224.813 114.415 141.475 207.851 144.499
    Accrued Expenses 729.903 648.483 571.753 610.553 581.499
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 1083.84 876.323 820.14 870.713 797.267
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 129.124 113.425 106.912 52.309 71.269
    Total Equity 2550.42 2619.06 2723.16 2803.82 2821.81
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.189 0.188 0.187 0.187 0.185
    Additional Paid-In Capital 5302.24 5155.38 5048.35 4954.47 4824.81
    Retained Earnings (Accumulated Deficit) -2756.4 -2540.61 -2329.08 -2154.35 -2006.18
    Other Equity, Total 4.394 4.108 3.708 3.51 2.995
    Total Liabilities & Shareholders’ Equity 3634.26 3495.38 3543.3 3674.53 3619.08
    Total Common Shares Outstanding 188.628 187.672 187.289 186.559 185.234
    Other Current Assets, Total 0.592 0.819 1.189 3.546 5.769
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -610.308 -674.471 613.67 -158.65 -222.693
    Cash From Operating Activities -453.751 -499.007 856.568 -163.737 -203.536
    Cash From Operating Activities 46.727 42.854 36.045 23.774 26.032
    Non-Cash Items 236.74 196.991 149.701 83.902 70.676
    Changes in Working Capital -150.54 -88.016 42.86 -112.763 -53.898
    Cash From Investing Activities 228.237 288.884 -1419.01 -277.729 -592.63
    Capital Expenditures -77.34 -52.33 -82.409 -70.753 -21.219
    Other Investing Cash Flow Items, Total 305.577 341.214 -1336.6 -206.976 -571.411
    Cash From Financing Activities 125.36 77.779 846.108 637.842 713.407
    Issuance (Retirement) of Stock, Net 125.36 77.779 846.108 637.842 713.407
    Net Change in Cash -101.348 -133.59 283.862 196.376 -82.759
    Deferred Taxes 0.553 0.548 -2.053 0 -23.653
    Amortization 23.077 23.087 16.345
    Foreign Exchange Effects -1.194 -1.246 0.198
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -174.737 -610.308 -462.137 -271.321 -136.494
    Cash From Operating Activities -249.643 -453.751 -374.311 -288.582 -216.812
    Cash From Operating Activities 12.423 46.727 34.642 22.867 11.402
    Amortization 5.69 23.077 17.261 11.444 5.691
    Non-Cash Items 56.881 236.74 175.039 111.744 49.828
    Changes in Working Capital -150.111 -150.54 -138.895 -162.759 -147.394
    Cash From Investing Activities 232.336 228.237 264.727 199.756 26.663
    Capital Expenditures -38.655 -77.34 -48.095 -32.161 -17.397
    Other Investing Cash Flow Items, Total 270.991 305.577 312.822 231.917 44.06
    Cash From Financing Activities 29.937 125.36 60.013 41.624 26.664
    Issuance (Retirement) of Stock, Net 42.24 125.36 60.013 41.624 26.664
    Foreign Exchange Effects 0.92 -1.194 -6.893 -2.809 -0.353
    Net Change in Cash 13.55 -101.348 -56.464 -50.011 -163.838
    Deferred Taxes 0.211 0.553 -0.221 -0.557 0.155
    Financing Cash Flow Items -12.303
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Baker Bros. Advisors LP Hedge Fund 23.7372 44554162 -4088 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.0615 13254362 152154 2023-06-30 LOW
    Pentwater Capital Management LP Hedge Fund 5.1303 9629500 7874500 2023-06-30 HIGH
    Capital World Investors Investment Advisor 4.8383 9081409 -3188031 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.4223 8300626 477794 2023-06-30 LOW
    Capital International Investors Investment Advisor 3.4189 6417224 -810641 2023-06-30 LOW
    PRIMECAP Management Company Investment Advisor 3.2173 6038808 1144000 2023-06-30
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.7764 3334204 -20028 2023-06-30 LOW
    Invesco Capital Management (QQQ Trust) Investment Advisor 1.7036 3197608 19941 2023-09-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.2007 2253733 -4575730 2023-06-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.1652 2187105 473466 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.0984 2061760 87737 2023-06-30 LOW
    Barclays Bank PLC Investment Advisor 1.0279 1929326 1775088 2023-06-30 MED
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 0.9375 1759606 -42300 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.8703 1633535 893994 2023-06-30 HIGH
    JP Morgan Asset Management Investment Advisor 0.8545 1603838 -765853 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 0.701 1315820 -117574 2023-06-30 LOW
    BlackRock Asset Management Ireland Limited Investment Advisor 0.5989 1124091 250655 2023-06-30 LOW
    DWS Investments UK Limited Investment Advisor 0.4813 903451 720565 2023-06-30 LOW
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.4722 886400 77328 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Seattle Company profile

    Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
    Industry: Biotechnology & Medical Research (NEC)

    21823 30Th Drive Se
    Suite
    BOTHELL
    WASHINGTON 98021
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    43,684.00 Price
    -0.740% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading